SABS

SAB Biotherapeutics Inc. (SABS) | Rumor.io

SAB Biotherapeutics

SABS

Attention (50-day avg)0%

Attention rank (50-day avg)#4,207

Bullish sentiment (50-day avg)0%

Price to earnings ratio14

Market capitalization292.5M

Earnings per share0.23

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)13.3M

Social

What share of all stock conversation is about SABS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

May 11

$SABS is expected to see a potential pop, with some traders coiling for a move.
The FDA's missed PDUFA date for Sanofi's teplizumab and the company's attempt to pull its CNPV may be affecting $SABS.
Some researchers describe SAB-163, a treatment for hantavirus, as one of the most advanced antibody-based countermeasures, potentially leading to a significant price increase.

Generated by AI

Sentiment

Of the messages about SABS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0%	90.94% -1.55
Bearish	—	100%	100%	9.06% +1.55

Bullish· Jul 21

SAB Biotherapeutics, Inc. (SABS) has seen a significant 98% increase in value, with some traders locking in profits.
The company has secured a $175M private placement, which has attracted major investors and could lead to further growth.
SABS is well-positioned for a potential run to $7, with many traders and investors optimistic about its future prospects.

Bearish· Jul 21

The stock's price increase has been largely erased, with it returning to its opening price after a significant jump.
The company has submitted a dilution filing, which could lead to a decline in the stock's value.
The stock's short position has been profitable, with some traders making a $5k profit after shorting the stock and watching it decline.

Generated by AI

Topics

Of the messages about SABS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	51.91%
Analysts	—	—	0%	25.22%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	4.4%
Technical Analysis	—	—	0%	18.48%

Analysts· Nov 2

Baird analyst Coleen Kusy initiated coverage of SAB Biotherapeutics with an Outperform rating and a $23 price target.
Analysts are very confident about SAB Biotherapeutics, with a 100% buy consensus based on analysis from two analysts.
The price target of $23 for SAB Biotherapeutics was announced by Baird, and the stock surged 33% after hours.

Announcements· May 21

SAB Biotherapeutics' ($SABS) FDA has cleared the IND application for SAB-142, a type 1 diabetes therapy, allowing for clinical development in the US.
The clearance enables the company to enroll patients with type 1 diabetes in the HUMAN trial, a phase 1 clinical study designed to assess the safety and efficacy of SAB-142.
SAB Biotherapeutics announced decent earnings and FDA clearance for the IND application, providing a catalyst for the company's stock.

Generated by AI

Community

Of the messages about SABS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	50%	50%	48.22%
Newcomers	0%	50%	50%	51.78%

Regulars· May 4

SAB Biotherapeutics ($SABS) presented positive Phase 1 and 2a data for its influenza immunotherapy, SAB-176, at the ISIRV-AVG conference.
The stock has seen significant price movements, with a 35.9% gain after being mentioned and a 47% gain since the day's earlier tweet, prompting questions about its potential for continued growth.
The short float on $SABS is 0.4%, indicating a low level of short selling, and the stock's price has reached 1.06 with a float of 28.6M.

Newcomers· May 7

Newcomers to the market are focusing on the potential for SAB Biotherapeutics ($SABS) to benefit from the recent hantavirus news, with some speculating that the stock could pump to $50.
The company's hantavirus treatment, SABS-159, is being developed in partnership with EBS, and some are curious about the potential for a public relations (PR) update or announcement from SAB Biotherapeutics.
Some traders are taking a speculative approach to SAB Biotherapeutics, hoping for a significant increase in the stock's value, potentially similar to the performance of VXRT during the COVID-19 pandemic, while others are taking a more cautious approach.

Generated by AI

News

SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...

1mo agoYahoo Finance

Earnings call transcript: SAB Bio posts wider Q2 2026 loss as trial momentum builds

1mo agoInvesting.com

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected in 2H 2027 Breakthrough T1D awarded a grant to PRISE‑hATG study of SAB‑142 in patients with Stage 3 type 1 diabetes who are 100 days to 2 years from diagnosis Operational runway through 2028 to support SAFEGUARD study, PRISE-hATG study and pre-commercial activities Conference call today at 8:30 AM ET

1mo agoYahoo Finance

Also Discussed

Investors talking about SABS also mention

#	Name	Attention
1	Better Therapeutics, Inc.BTTX	0%new
2	Bone Biologics CorpBBLG	0%+0
3	MAQC - Maquia Capital Acquisition Corporation	——
4	BSLK - Bolt Projects Holdings, Inc.	——
5	FIAC - Focus Impact Acquisition Corp.	——
6	ZIMV - ZimVie Inc.	——
7	KACL - Kairous Acquisition Corp. Limited	——
8	MODV - ModivCare Inc.	——
9	PGRU - PropertyGuru Limited	——
10	Vir Biotechnology, Inc.VIR	0%+0

SAB Biotherapeutics Inc.

Healthcare
Biotechnology

SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal immunotherapies for immune and autoimmune disorders, as well as infectious diseases. The company’s platform is designed to produce high-potency antibody therapies without relying on human donors or convalescent plasma, using a proprietary approach to generate targeted immunoglobulins. Its current pipeline is centered on SAB-142, a lead product candidate being developed for autoimmune type 1 diabetes. SAB Biotherapeutics Inc. also applies its DiversitAb platform to create multi-target antibody medicines intended for difficult-to-treat conditions across immunology and infectious disease. Based in the United States, the company operates in the biotechnology sector, where it contributes to the development of next-generation antibody-based treatments for patients with significant unmet medical needs.

Website

Location

777 W 41st St.

Miami Beach, FL, 33140

United States

Social

What share of all stock conversation is about SABS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

May 11

$SABS is expected to see a potential pop, with some traders coiling for a move.
The FDA's missed PDUFA date for Sanofi's teplizumab and the company's attempt to pull its CNPV may be affecting $SABS.
Some researchers describe SAB-163, a treatment for hantavirus, as one of the most advanced antibody-based countermeasures, potentially leading to a significant price increase.

Generated by AI

Sentiment

Of the messages about SABS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0%	90.94% -1.55
Bearish	—	100%	100%	9.06% +1.55

Bullish· Jul 21

SAB Biotherapeutics, Inc. (SABS) has seen a significant 98% increase in value, with some traders locking in profits.
The company has secured a $175M private placement, which has attracted major investors and could lead to further growth.
SABS is well-positioned for a potential run to $7, with many traders and investors optimistic about its future prospects.

Bearish· Jul 21

The stock's price increase has been largely erased, with it returning to its opening price after a significant jump.
The company has submitted a dilution filing, which could lead to a decline in the stock's value.
The stock's short position has been profitable, with some traders making a $5k profit after shorting the stock and watching it decline.

Generated by AI

Topics

Of the messages about SABS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	51.91%
Analysts	—	—	0%	25.22%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	4.4%
Technical Analysis	—	—	0%	18.48%

Analysts· Nov 2

Baird analyst Coleen Kusy initiated coverage of SAB Biotherapeutics with an Outperform rating and a $23 price target.
Analysts are very confident about SAB Biotherapeutics, with a 100% buy consensus based on analysis from two analysts.
The price target of $23 for SAB Biotherapeutics was announced by Baird, and the stock surged 33% after hours.

Announcements· May 21

SAB Biotherapeutics' ($SABS) FDA has cleared the IND application for SAB-142, a type 1 diabetes therapy, allowing for clinical development in the US.
The clearance enables the company to enroll patients with type 1 diabetes in the HUMAN trial, a phase 1 clinical study designed to assess the safety and efficacy of SAB-142.
SAB Biotherapeutics announced decent earnings and FDA clearance for the IND application, providing a catalyst for the company's stock.

Generated by AI

Community

Of the messages about SABS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	50%	50%	48.22%
Newcomers	0%	50%	50%	51.78%

Regulars· May 4

SAB Biotherapeutics ($SABS) presented positive Phase 1 and 2a data for its influenza immunotherapy, SAB-176, at the ISIRV-AVG conference.
The stock has seen significant price movements, with a 35.9% gain after being mentioned and a 47% gain since the day's earlier tweet, prompting questions about its potential for continued growth.
The short float on $SABS is 0.4%, indicating a low level of short selling, and the stock's price has reached 1.06 with a float of 28.6M.

Newcomers· May 7

Newcomers to the market are focusing on the potential for SAB Biotherapeutics ($SABS) to benefit from the recent hantavirus news, with some speculating that the stock could pump to $50.
The company's hantavirus treatment, SABS-159, is being developed in partnership with EBS, and some are curious about the potential for a public relations (PR) update or announcement from SAB Biotherapeutics.
Some traders are taking a speculative approach to SAB Biotherapeutics, hoping for a significant increase in the stock's value, potentially similar to the performance of VXRT during the COVID-19 pandemic, while others are taking a more cautious approach.

Generated by AI

SAB Biotherapeutics

Social

May 11

Bullish· Jul 21

Bearish· Jul 21

Analysts· Nov 2

Announcements· May 21

Regulars· May 4

Newcomers· May 7

SAB BIO at Citi summit: trial progress and a bigger t1d bet

SAB BIO to Participate in Upcoming Investor Conferences

SAB Biotherapeutics Q2 Earnings Call Highlights

SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...

Earnings call transcript: SAB Bio posts wider Q2 2026 loss as trial momentum builds

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

Also Discussed

SAB Biotherapeutics Inc.

Company Information

Location

SAB BIO at Citi summit: trial progress and a bigger t1d bet

SAB BIO to Participate in Upcoming Investor Conferences

SAB Biotherapeutics Q2 Earnings Call Highlights

SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...

Earnings call transcript: SAB Bio posts wider Q2 2026 loss as trial momentum builds

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

Also Discussed

Social

May 11

Bullish· Jul 21

Bearish· Jul 21

Analysts· Nov 2

Announcements· May 21

Regulars· May 4

Newcomers· May 7